ASCO 2013 Intro

Article

Cancer Network and the journal ONCOLOGY present exclusive coverage from the annual meeting of the American Society of Clinical Oncology (ASCO). Visit one of our topic-specific ASCO pages or follow the stories below to catch some of the most important information to come out of this year's event.

Cancer Network and the journal ONCOLOGY present exclusive coverage from the annual meeting of the American Society of Clinical Oncology (ASCO). Visit one of our topic-specific ASCO pages or follow the stories below to catch some of the most important information to come out of this year's event.

 

• ASCO 2013 Breast Coverage

• ASCO 2013 Lung Cancer Coverage

• ASCO 2013 Prostate Cancer Coverage

Recent Videos
4 experts are featured in this series.
The poly-ICLC trial seeks to develop a delivery mechanism to prostate cancer through different biomarkers.
Related Content
Micheal P. Bogenschutz, MD, discussed addressing unmet needs, implementation, and adverse effects related to psilocybin-assisted psychotherapy in cancer.

Integrating Psilocybin-Assisted Psychotherapy in Comprehensive Cancer Care

Michael P. Bogenschutz, MD
January 20th 2025
Article

Micheal P. Bogenschutz, MD, discussed addressing unmet needs, implementation, and adverse effects related to psilocybin-assisted psychotherapy in cancer.

Michael P. Bogenschutz, MD, discusses the efficacy, safety, implementation, and future research of psilocybin for cancer-related psychological events.

Psilocybin May Help Address Cancer-Related Psychological Concerns

Michael P. Bogenschutz, MD
January 20th 2025
Podcast

Michael P. Bogenschutz, MD, discusses the efficacy, safety, implementation, and future research of psilocybin for cancer-related psychological events.

FDA Grants Breakthrough Device Designation to Biosignature Test in DCIS

FDA Grants Breakthrough Device Designation to Biosignature Test in DCIS

Tim Cortese
January 18th 2025
Article

The DCISionRT test has shown to be a significant factor in a clinician’s recommendation on whether a patient with DCIS should receive radiotherapy.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Seattle-based Clinicians on Effective Treatment Combos in EGFR-Mutated NSCLC

Seattle-based Clinicians on Effective Treatment Combos in EGFR-Mutated NSCLC

ONCOLOGY Staff
January 17th 2025
Article

A panel of experts met to discuss the best treatment options for patients with EGFR or TP53-mutated non–small cell lung cancer.

Advancement of First-Line Treatments on EGFR-Mutated NSCLC

Advancement of First-Line Treatments on EGFR-Mutated NSCLC

ONCOLOGY Staff
January 17th 2025
Article

As part of a Satellite Sessions program focused on the Cleveland Clinic and surrounding institutions, CancerNetwork hosted a panel discussion on treatment options for patients with EGFR-mutated NSCLC.